Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

BMS Nabs Global Rights to Ambrx' Fibroblast Growth Factor and Relaxin Candidates for $24M

Preclinical programs for the treatment of type 2 diabetes and heart failure are based on Ambrx’ amino acid-based protein modification platform.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

GEN’s Hall of Shame

Will you be voting for any of the candidates on GEN’s Hall of Shame list in the next election?

Suggest a Poll